Dr. Feldman on Challenges Facing the Development of Biomarkers for Prostate Cancer

Adam Scott Feldman, MD, MPH
Published: Wednesday, Aug 02, 2017



Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer.

An important challenge facing the development of biomarkers is the potential of false positives, explains Feldman. Additionally, since there are so much data being investigated, it takes time to go through each data set, states Feldman.



Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer.

An important challenge facing the development of biomarkers is the potential of false positives, explains Feldman. Additionally, since there are so much data being investigated, it takes time to go through each data set, states Feldman.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x